Furthermore, the role of GLP-1R agonists in the treatment of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) is being actively explored (Siddeeque et al., 2024). This evidence concerns the gene GLP1R and Parkinson disease.